Table II.

Multivariate analysis of risk factors for nonmelanoma skin cancer among allogeneic hematopoietic cell transplant recipients

	NMSC		SCC		BCC
Variable	Hazard ratio (95% CI)	P value	Hazard ratio (95% CI)	P value	Hazard ratio (95% CI)	P value
Voriconazole exposure*†	1.82 (1.13–2.91)	.013	2.25 (1.30–3.89)	.004	1.05 (0.44–2.52)	.913
Chronic GVHD†	1.80 (1.03–3.12)	.038	1.88 (0.98–3.62)	.058	2.49 (0.89–6.98)	.084
Age at HCT	1.07 (1.04–1.10)	<.001	1.08 (1.04–1.11)	<.001	1.06 (1.02–1.12)	.010
Male sex	3.67 (2.00–6.78)	<.001	4.34 (2.03–9.26)	<.001	2.20 (0.78–6.19)	.137
White race	12.60 (3.02–52.52)	<.001	15.75 (2.17–114.48)	.007	5.85 (0.76–45.18)	.090
History of NMSC	10.95 (5.84–20.52)	<.001	4.64 (2.31–9.30)	<.001	8.35 (2.77–25.16)	<.001

BCC, Basal cell carcinoma; CI, confidence interval; GVHD, graft-versus-host disease; HCT, hematopoietic cell transplantation; NMSC, nonmelanoma skin cancer; SD, standard deviation.

^*Voriconazole exposure included both pretransplant and post-transplant exposure.

^†Voriconazole exposure and diagnosis of chronic GVHD were calculated as time-dependent variables.